Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01572662 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT01572662: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01572662 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 201 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01572662, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving busulfan and fludarabine before a stem cell transplant can help control the disease better than the standard method in patients with leukemia, lymphoma, multiple myeloma, MDS, or MPD. In this study, 2 doses of busulfan will be given 2 weeks before a stem cell transplant followed by 4 doses of busulfan and fludarabine during the week before the stem cell transplant, rather than the standard method of giving 4 doses of busulfan and fludarabine only during the week before the stem cell transplant. The safety of this combination therapy will also be studied. Busulfan is designed to kill cancer cells by binding to DNA (the genetic material of cells), which may cause cancer cells to die. Busulfan is commonly used in stem cell transplants. Fludarabine is designed to interfere with the DNA of cancer cells, which may cause the cancer cells to die.
Interventions
- DRUG Busulfan
- DRUG Tacrolimus
- DRUG Methotrexate
- DRUG Fludarabine monophosphate
- PROCEDURE Stem Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2012-04-11 |
| Est. Completion | 2022-08-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01572662
The ClinicalTrials.gov registry entry for NCT01572662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Busulfan is the first listed.
NCT01572662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01572662 about?
NCT01572662 is a clinical study titled "Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning". The goal of this clinical research study is to learn if giving busulfan and fludarabine before a stem cell transplant can help control the disease better than the standard method in patients with leukemia, lymphoma, multiple myeloma, MDS, or MPD. In this study, 2 doses of busulfan will be given 2 we...
What is the current status of trial NCT01572662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2012-04-11. Estimated completion is 2022-08-11.
What interventions are being tested in trial NCT01572662?
The interventions under investigation include: Busulfan (DRUG), Tacrolimus (DRUG), Methotrexate (DRUG), Fludarabine monophosphate (DRUG), Stem Cell Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT01572662?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.